Elisabeth Pérez-Ruiz

22PUBLICATIONS
50CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 07, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|Mar 31, 2026
Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma.

Juan Luis Onieva, Elisabeth Pérez-Ruiz, Ville Vilkki

|Feb 27, 2026
Association of IL7 rs16906115 Polymorphism with Immune-Related Adverse Events in Patients with Advanced Lung Cancer Undergoing Immunotherapy.

Andrea González-Hernández, Guillermo Paz-López, Beatriz Martínez-Gálvez

|Dec 05, 2025
Contrasting outcomes of inherited NOD2 loss-of-function variants on immunotherapy response in cancer.

Nora Bousdar, Elisabeth Pérez-Ruiz, Isabel Barragán

|Apr 12, 2025
Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer.

José Miguel Jurado, Vanesa Gutiérrez, Alexandra Cantero

|Sep 12, 2024
Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review.

Mora Guardamagna, May-Lucie Meyer, Miguel Ángel Berciano-Guerrero

Pageof 4

Frequent Collaborators

8 joint publications

Javier Oliver

8 joint publications

Isabel Barragán

7 joint publications

Miguel-Angel Berciano-Guerrero

6 joint publications

Juan-Luis Onieva-Zafra